SCHEMBL9666252

SCHEMBL9666252

CCCCCC(=O)NC(Cc1ccccc1)C(=O)O

nearest known ligand 0.79

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FAAH O00519 2/20 0.79
PSMB5 P28074 3/20 0.63
ITGB3 P05106 2/20 0.63
ITGA2B P08514 2/20 0.63
ACE P12821 2/20 0.58
CTSG P08311 1/20 0.58
CMA1 P23946 1/20 0.58
ALDH1A1 P00352 1/20 0.58
HDAC3 O15379 1/20 0.57
HDAC4 P56524 1/20 0.57
HDAC1 Q13547 1/20 0.57
HDAC7 Q8WUI4 1/20 0.57
HDAC2 Q92769 1/20 0.57
HDAC10 Q969S8 1/20 0.57
HDAC11 Q96DB2 1/20 0.57
HDAC8 Q9BY41 1/20 0.57
HDAC6 Q9UBN7 1/20 0.57
HDAC9 Q9UKV0 1/20 0.57
HDAC5 Q9UQL6 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8467930 1.00 FAAH (0.79) FAAHPSMB5ITGB3ITGA2BACE
SCHEMBL15285319 0.99 FAAH (0.81) FAAHPSMB5ITGB3ITGA2BHDAC3
SCHEMBL1815009 0.99 FAAH (0.81) FAAHPSMB5ITGB3ITGA2BHDAC3
SCHEMBL9716823 0.99 FAAH (0.81) FAAHPSMB5ITGB3ITGA2BHDAC3
SCHEMBL9506671 0.99 FAAH (0.81) FAAHPSMB5ITGB3ITGA2BHDAC3
SCHEMBL22494095 0.99 FAAH (0.81) FAAHPSMB5ITGB3ITGA2BHDAC3
SCHEMBL22494096 0.99 FAAH (0.81) FAAHPSMB5ITGB3ITGA2BHDAC3
SCHEMBL22494097 0.99 FAAH (0.81) FAAHPSMB5ITGB3ITGA2BHDAC3
SCHEMBL21998924 0.99 FAAH (0.81) FAAHPSMB5ITGB3ITGA2BHDAC3
SCHEMBL1815011 0.99 FAAH (0.81) FAAHPSMB5ITGB3ITGA2BHDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0473700-A1 AN ENZYME-CATALYZED PROCESS FOR PREPARING N-ACYL AMINO ACIDS AND N-ACYL AMINO ACID AMIDES NOVO NORDISK A/S (DK) 1992-03-11 EP claimed
WO-1990014429-A1 AN ENZYME-CATALYZED PROCESS FOR PREPARING N-ACYL AMINO ACIDS AND N-ACYL AMINO ACID AMIDES NOVO NORDISK A/S (DK) 1990-11-29 WO claimed
US-4757066-A Reduces renal toxicity SANKYO COMPANY LIMITED (JP) 1988-07-12 US claimed
US-20250000948-A1 SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID ADOCIA (FR) 2025-01-02 US disclosed
EP-4299057-A1 SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID Adocia (FR) 2024-01-03 EP disclosed
WO-2023084118-A1 SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID ADOCIA (FR) 2023-05-19 WO disclosed
EP-4180060-A1 SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID Adocia (FR) 2023-05-17 EP disclosed
WO-2021070696-A1 CYCLIC PEPTIDE HAVING CTLA-4 INHIBITORY ACTIVITY AND USE THEREOF ジーンフロンティア株式会社 2021-04-15 WO disclosed
CN-108976146-A The positive positive hexanoyl ArAA of hexanoyl ammonia first cyclic amide base of amino, synthesis, activity and application 首都医科大学 2018-12-11 CN disclosed
CN-106470665-A Have and reduce the cosmetic composition stimulating 宝洁公司 2017-03-01 CN disclosed
CN-103189522-B Novel artificial translation/synthesisystem system THE UNIVERSITY OF TOKYO (JP) 2015-12-09 CN disclosed
US-20140288142-A1 NITRIC OXIDE DONOR COMPOUNDS NICOX SA (FR) 2014-09-25 US disclosed
CN-103189522-A Novel artificial translation/synthesis system UNIV TOKYO 2013-07-03 CN disclosed
EP-0178911-B1 COMPOSITION CONTAINING A PENEM OR CARBAPENEM ANTIBIOTIC SANKYO COMPANY LIMITED (JP) 1992-01-22 EP disclosed
US-4757066-A Reduces renal toxicity SANKYO COMPANY LIMITED (JP) 1988-07-12 US disclosed
EP-0178911-A2 Composition containing a penem or carbapenem antibiotic SANKYO COMPANY LIMITED (JP) 1986-04-23 EP disclosed
US-4151198-A Resolution of N-acyl-DL (+)-phenylalanines AMERICAN CYANAMID COMPANY (US) 1979-04-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140288142-A1 NITRIC OXIDE DONOR COMPOUNDS NOS3, NOS2, NOS1 FAAH 1868/4885PSMB5 3837/4885ITGB3 191/4885
US-20250000948-A1 SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID NPPA, BCAT1, ANPEP FAAH 858/4885PSMB5 612/4885ITGB3 4058/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.